US Edition
At Bernese Vaccine Manufacturer, 300 Employees Tremble at the Job
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.6 Articles
6 Articles
As part of a "strategic review", Johnson & Johnson is considering closing the Janssen vaccine factory. The latest development of a new active substance was unsuccessfully completed.
The failure of a new vaccine as well as the opening of a much larger plant in the Netherlands could lead to the closure of Janssen's activities in BernThe vaccine developer Janssen is studying the possibility of closing his factory in Bern-Bümplitz. On Tuesday he opened a consultation procedure with employees to find alternatives. Up to 300 employees could be affected by a closure of the plant.Two reasons explain the reflections on the closure o…
watson.ch/
HandelszeitungAs the subsidiary of US pharmaceutical giant Johnson & Johnson announced on Tuesday, there are two reasons for considering closing the plant in Bern.
pme.ch
rfj.chThe vaccine developer Janssen is studying the possibility of closing his factory in Bern-Bümplitz. On Tuesday he opened a consultation procedure with employees to find alternatives. Up to 300 employees could be affected by a closure of the plant.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
